Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for the treatment of presbyopia and dim light or night vision disturbances; APX3330, a small-molecule inhibitor of Ref-1 that has completed Phase II clinical trial for the treatment of diabetic retinopathy; andOPGx-LCA5, an early-onset retinal degeneration which is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; OPGx-BEST1, developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies. Its other pre-clinical IRD pipeline, including OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-GNGB. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.